Volume 10, Number 6—June 2004
Reference Group Choice and Antibiotic Resistance Outcomes
|OR (95% CI)b||Attributable to MRSA||p value|
|Three analyses comparing MRSA and uninfected controls
||(n = 121)
||(n = 193)
||11.4 (2.8 to 34.9)c
|Hospital days after surgery, mean per case
||3.2 (2.7 to 3.7)d
|Charges ($), mean/case
||2.2 (2.0 to 2.6)e
|Three analyses comparing MRSA and MSSA controls
||(n = 121)
||(n = 165)
|Hospital days after infection, mean per case
|Charges ($), mean per case||118,414||73,165||1.2h||13,901||0.03|
aOR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
bOdds ratio for deaths, and multiplicative effect (ME) for continuous outcomes (length of stay and charges).
cAdjusted for American Society of Anesthesiologists-Physical Status (ASA) score >3 and age.
dAdjusted for ASA score, duration of surgery, hospital, renal disease, diabetes and length of hospital stay before surgery.
eAdjusted for ASA score, hospital, duration of surgery, renal disease, length of hospital stay, and intensive care unit (ICU) stay before surgery.
fAdjusted for ASA score >3, duration of surgery, and age.
gAdjusted for ASA score, renal disease, diabetes mellitus, hospital, duration of surgery, and length of stay before infection.
hAdjusted for ASA score, duration of surgery, length of hospital and ICU stay before infection, hospital, renal disease and diabetes.
- Page created: February 22, 2011
- Page last updated: February 22, 2011
- Page last reviewed: February 22, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)